Scholarlink

<p>We conducted a multicenter retrospective analysis of 408 patients diagnosed with onychomycosis who attended three tertiary care Spanish hospitals. The study was conducted to assess the clinical characteristics and outcomes of onychomycosis patients undertaken combined treatment with ciclopirox 8% hydroxypropyl chitosan (CPX 8% HPCH) nail lacquer and oral antifungal agents (terbinafine, itraconazole, and fluconazole). Data were extracted and analyzed using the EHRead<sup>®</sup> technology based on natural language processing and machine learning and using SNOMED CT terminology. The mean age was 51.1 years, with 54.4% females. Repeated nail trauma was the most common risk factor (7.1%). More than half of the patients (56.6%) underwent fungal culture. Terbinafine, itraconazole, and fluconazole were used in 67.7%, 20.8%, and 11.5% of patients, respectively. Treatment synchronicity distribution revealed that 59.1% of patients started concomitant treatment with CPX 8% HPCH and oral antifungals, 27.9% had initial oral antifungals, and 13% had initial nail lacquer. The response to treatment (positive response 15.7%, presumed positive 59.8%) was unrelated to treatment synchronicity or type of antifungal agent. Erythema (5.6%), diarrhea (4.9%), and fever (4.2%) were the most frequently registered potential adverse events. These findings provide valuable insights for physicians regarding the management of patients with onychomycosis in daily practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Retrospective study of onychomycosis patients treated with ciclopirox 8% HPCH and oral antifungals applying artificial intelligence to electronic health records

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Gastón Roustan,
  • José Luis López Estébaranz,
  • Pablo De La Cueva,
  • Lucía Cabal-Hierro,
  • David Casadevall,
  • Víctor Fanjul,
  • Judith Marín-Corral,
  • Luisa Martínez,
  • Claudia Maté,
  • Sebastian Menke,
  • Natalia Polo,
  • Margarita Posso,
  • Ignacio Salcedo,
  • Daniel Salvador,
  • Miren Taberna,
  • Francesca Pajuelo,
  • María Luisa Tamarit,
  • Aida Valmaseda,
  • Jordi Galván

摘要

We conducted a multicenter retrospective analysis of 408 patients diagnosed with onychomycosis who attended three tertiary care Spanish hospitals. The study was conducted to assess the clinical characteristics and outcomes of onychomycosis patients undertaken combined treatment with ciclopirox 8% hydroxypropyl chitosan (CPX 8% HPCH) nail lacquer and oral antifungal agents (terbinafine, itraconazole, and fluconazole). Data were extracted and analyzed using the EHRead® technology based on natural language processing and machine learning and using SNOMED CT terminology. The mean age was 51.1 years, with 54.4% females. Repeated nail trauma was the most common risk factor (7.1%). More than half of the patients (56.6%) underwent fungal culture. Terbinafine, itraconazole, and fluconazole were used in 67.7%, 20.8%, and 11.5% of patients, respectively. Treatment synchronicity distribution revealed that 59.1% of patients started concomitant treatment with CPX 8% HPCH and oral antifungals, 27.9% had initial oral antifungals, and 13% had initial nail lacquer. The response to treatment (positive response 15.7%, presumed positive 59.8%) was unrelated to treatment synchronicity or type of antifungal agent. Erythema (5.6%), diarrhea (4.9%), and fever (4.2%) were the most frequently registered potential adverse events. These findings provide valuable insights for physicians regarding the management of patients with onychomycosis in daily practice.